Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer.
Survival Outcomes with Photodynamic Therapy, Chemotherapy and Radiation in Patients with Stage III or Stage IV Non-Small Cell Lung Cancer.
复制标题
光动力疗法、化疗和放疗对III期或IV期非小细胞肺癌患者的生存结局。
DOI：
10.3390/cancers13040803
复制
发表时间：
2021-02-15
期刊：
影响因子：
5.2
通讯作者：
Jayadevappa R
中科院分区：
文献类型：
--
作者：
Chhatre S;Vachani A;Allison RR;Jayadevappa R
光动力疗法（PDT）与肺癌患者死亡率之间的关系尚不清楚。我们使用2004年至2016年的国家癌症数据库（NCDB）研究了PDT与III/IV期非小细胞肺癌（NSCLC）患者死亡率之间的相关性。从NCDB中，我们确定了治疗代码为消融（包括PDT）的患者。从2000年至2013年的医疗保险和医疗补助数据中，我们确定了接受PDT的NSCLC患者，并使用这些患者来确认PDT治疗。我们评估了PDT与死亡率之间的关系。研究组包括147例PDT +放疗+化疗患者，227，629例放疗+化疗患者，106，667例单纯放疗患者和122，193例单纯化疗患者。与单纯放疗组相比，PDT组和放疗加化疗组的死亡风险较低（分别降低50%和53%）。在不适合手术的III期或IV期NSCLC患者中，在化疗和放疗的基础上增加PDT比单独放疗提供了生存益处。关于光动力疗法（PDT）与肺癌患者死亡率之间的相关性的数据有限。我们使用2004年至2016年美国国家癌症数据库（NCDB）的数据分析了PDT与III期或IV期非小细胞肺癌（NSCLC）患者死亡率之间的相关性。从NCDB中，我们确定了接受激光消融/冷冻手术或局部肿瘤破坏/切除（包括PDT）的患者。从2000年至2013年的医疗保险和医疗补助索赔中，我们确定了接受PDT治疗的NSCLC患者和接受支气管镜检查的患者，然后使用这些患者来确认PDT治疗。从NCDB中，我们提取了接受放疗联合化疗、单纯放疗或单纯化疗的NSCLC患者。我们使用生存分析来确定PDT和死亡率之间的关系。在2004年至2016年期间，确定了457，556例III期或IV期NSCLC患者，其中147例接受PDT联合放疗和化疗，227，629例接受放疗联合化疗，106，667例仅接受放疗，122，193例仅接受化疗。与单纯放疗组相比，PDT组和放疗加化疗组的死亡风险较低（分别降低50%和53%）。在患有III期或IV期疾病的NSCLC患者中，在放射治疗中添加PDT比单独放射治疗提供生存益处。
The association between photodynamic therapy (PDT) and mortality in lung cancer patients remains unclear. We studied the association between PDT and mortality in patients with stage III/IV non-small cell lung cancer (NSCLC) using the National Cancer Database (NCDB) between 2004 and 2016. From the NCDB, we identified patients whose treatment code was ablation (including PDT). From Medicare and Medicaid data between 2000 and 2013, we identified NSCLC patients receiving PDT and used these to confirm PDT treatment. We assessed the association between PDT and mortality. Study groups consisted of 147 patients with PDT + radiation + chemotherapy, 227,629 with radiation + chemotherapy, 106,667 with radiation therapy alone and 122,193 with chemotherapy alone. Compared to the radiation alone group, the PDT group and radiation with chemotherapy group had lower risk of mortality (50% and 53% lower, respectively). Among the NSCLC patients with stage III or stage IV disease not eligible for surgery, the addition of PDT to chemotherapy and radiation therapy offers survival benefit over radiation therapy alone. Data regarding the association between photodynamic therapy (PDT) and mortality in lung cancer patients are limited. We analyzed the association between PDT and mortality in patients with stage III or IV non-small cell lung cancer (NSCLC) using data from the National Cancer Database (NCDB) between 2004 and 2016. From the NCDB, we identified patients receiving laser ablation/cryosurgery or local tumor destruction/excision (which includes PDT). From Medicare and Medicaid claims between 2000 and 2013, we identified NSCLC patients receiving PDT and those receiving bronchoscopy, then used these to confirm the PDT treatment. From NCDB, we extracted NSCLC patients who received radiation with chemotherapy, radiation alone or chemotherapy alone. We used survival analysis to determine the association between PDT and mortality. Between 2004 and 2016, 457,556 NSCLC patients with stage III or stage IV were identified, of which 147 received PDT with radiation and chemotherapy, 227,629 received radiation with chemotherapy, 106,667 had radiation therapy alone and 122,193 received chemotherapy alone. Compared to the radiation alone group, the PDT group and radiation with chemotherapy group had lower hazard of mortality (50% and 53% lower, respectively). Among the NSCLC patients with stage III or stage IV disease, the addition of PDT to radiation therapy offers survival benefit over radiation therapy alone.
登录
查看更多内容
影响因子：
0.6
作者：
Lindenmann, J.;Matzi, V.;Smolle-Juettner, F.-M.
通讯作者：
Smolle-Juettner, F.-M.
DOI：
10.3322/caac.20114
发表时间：
2011-07
期刊：
CA: a cancer journal for clinicians
影响因子：
--
作者：
Agostinis P;Berg K;Cengel KA;Foster TH;Girotti AW;Gollnick SO;Hahn SM;Hamblin MR;Juzeniene A;Kessel D;Korbelik M;Moan J;Mroz P;Nowis D;Piette J;Wilson BC;Golab J
通讯作者：
Golab J
影响因子：
10
作者：
Freitag, L;Ernst, A;Macha, HN
通讯作者：
Macha, HN
影响因子：
7.2
作者：
DEYO, RA;CHERKIN, DC;CIOL, MA
通讯作者：
CIOL, MA
影响因子：
2.9
作者：
Ladha, Karim S.;Zhao, Kevin;Lee, Jarone
通讯作者：
Lee, Jarone